• Dasatinib (BMS-354825): Precision Kinase Inhibition in Tumor

  2026-07-01

  Explore how Dasatinib (BMS-354825) enables advanced research into tumor microenvironment signaling, with new insights on kinase inhibition in EMT and cancer stemness. This article uniquely bridges molecular mechanisms with practical assay design.

• Safe DNA Gel Stain: Elevating DNA and RNA Gel Stain Workflow

  2026-07-01

  Safe DNA Gel Stain from APExBIO redefines nucleic acid visualization by combining high sensitivity with a dramatically improved safety profile. Its blue-light excitation capabilities not only minimize DNA damage but also streamline workflows for cloning and molecular diagnostics, setting a new benchmark for DNA and RNA gel stain applications.

• Super-Enhancer Regulation of Disulfidptosis in Prostate Canc

  2026-06-30

  This study identifies a super-enhancer–FOXA1–SLC7A11 regulatory axis as a driver of disulfidptosis in prostate cancer, revealing how super-enhancers promote SLC7A11 expression and cytoskeletal collapse under glucose starvation. The findings suggest that targeting this pathway could provide new therapeutic strategies for advanced prostate cancer, especially in metabolically stressed tumor microenvironments.

• Anlotinib in Desmoplastic Small Round Cell Tumor: Case Evide

  2026-06-30

  This article reviews a unique clinical case and literature analysis demonstrating the efficacy of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating intra-abdominal desmoplastic small round cell tumor (IADSRCT). The findings highlight the therapeutic potential of multi-kinase inhibition for rare, aggressive sarcomas with limited treatment options.

• EGTA in Calcium Signaling: Workflows, Innovations & Troubles

  2026-06-29

  EGTA (egtzic acid) offers unparalleled precision in modulating calcium-dependent processes, enabling researchers to dissect mechanisms in neuroprotection, apoptosis, and vascular inflammation. This article provides actionable protocols, highlights innovations from recent endothelial research, and delivers troubleshooting insights to maximize experimental reliability using APExBIO’s EGTA.

• Pravastatin Sodium (SKU A4369): Reliable HMG-CoA Reductase I

  2026-06-29

  This article delivers an evidence-focused, scenario-driven exploration of Pravastatin sodium (SKU A4369) as a benchmark HMG-CoA reductase inhibitor in cell viability, proliferation, and cytotoxicity assays. By addressing common laboratory challenges with real-world Q&A, it guides researchers in optimizing experimental outcomes with reproducible, data-backed solutions. APExBIO’s formulation advantages and protocol parameters are highlighted for workflow reliability.

• Resazurin Sodium Salt: Fluorogenic Indicator for Cell Viabil

  2026-06-28

  Resazurin sodium salt stands out as a robust fluorogenic oxidation-reduction indicator, streamlining quantitative viability and cytotoxicity assessments across advanced biological models. Its application in high-throughput and imaging-based workflows enables sensitive, reproducible measurements—especially vital in disease modeling and drug discovery.

• Sorafenib (BAY-43-9006): Applied Workflows in Cancer Biology

  2026-06-27

  Sorafenib (BAY-43-9006) has become a cornerstone cancer biology research tool, enabling precise inhibition of key signaling pathways in both in vitro and in vivo models. This article demystifies advanced workflow integration, protocol optimization, and troubleshooting, leveraging APExBIO’s high-purity Sorafenib for robust, reproducible results.

• 2-NBDG Glucose Uptake Assay Kit: Advancing Cancer Metabolism

  2026-06-26

  The 2-NBDG Glucose Uptake Assay Kit empowers researchers to measure cellular glucose uptake rapidly and sensitively, streamlining workflows without radioactive hazards. Leveraging fluorescence-based detection, this kit enables single-cell analysis and precise interrogation of metabolic pathways—ideal for cancer, diabetes, and obesity research.

• ABT-199 (Venetoclax): BCL-2 Inhibition Beyond Hematology

  2026-06-26

  Explore how ABT-199, a potent Bcl-2 inhibitor, advances apoptosis research from hematologic malignancies to solid tumors. This article uniquely integrates high-content single-cell insights and protocol parameters to guide Venetoclax application in complex disease models.

• Trifluoperazine 2HCl: Advanced Dopamine D2 Receptor Inhibito

  2026-06-25

  Trifluoperazine 2HCl from APExBIO delivers nanomolar potency and exceptional solubility for high-sensitivity dopamine D2 receptor signaling studies, neuropharmacology assays, and macrophage modulation. This guide synthesizes protocol enhancements, troubleshooting strategies, and cross-disciplinary research applications to empower reproducible, insightful experimental outcomes.

• Berberine–Evodiamine Modulate GERD via TAS2R38/TRPV1 Pathway

  2026-06-25

  This study demonstrates that combined berberine and evodiamine treatment alleviates gastroesophageal reflux disease (GERD) through the TAS2R38/TRPV1-mediated regulation of MAPK/NF-κB signaling and macrophage polarization. The findings offer mechanistic insight into how targeting bitter taste and TRPV1 receptors can reduce esophageal inflammation, with implications for translational research on epithelial barrier restoration.

• Chenodeoxycholic Acid in CI-AKI Models: Protocols & Innovati

  2026-06-24

  Chenodeoxycholic Acid (CDCA) is redefining cholesterol metabolism and acute kidney injury research by precisely targeting FXR-KLF11 signaling. This guide translates the latest mechanistic insights and published protocols into actionable, bench-ready workflows—empowering researchers to optimize nuclear receptor signaling studies with confidence.

• JNJ-10198409: Precision Platelet-Derived Growth Factor Recep

  2026-06-23

  JNJ-10198409 empowers researchers with nanomolar precision in targeting PDGF-BB-driven signaling, enabling robust antiangiogenic and antiproliferative studies. Its versatility and potency streamline experimental workflows in cancer biology and fibrotic disorder research, backed by clear protocols and troubleshooting strategies.

• Dasatinib Monohydrate: Translational Leverage in Tumor Compl

  2026-06-23

  Explore how Dasatinib Monohydrate (BMS-354825) empowers translational researchers to navigate tumor heterogeneity, resistance mechanisms, and preclinical modeling—bridging mechanistic insight with strategic experimental guidance. This thought-leadership article integrates evidence from advanced assembloid models and highlights actionable workflow protocols, offering a visionary outlook for next-generation oncology research.

14889 records 1/993 page Next 12345 下5页 Last page